Sanofi and Regeneron expanded their antibody discovery and development collaboration, building on earlier partnerships. This framework provided the foundation for the co-development and co-commercialization of Dupixent (dupilumab, anti-IL-4R), which became one of the most successful biologic franchises in pharma history with >$13B in annual sales by 2024. The collaboration covers multiple antibody programs across immunology and oncology.